Enliven Therapeutics
ELVN
ELVN
45 hedge funds and large institutions have $735M invested in Enliven Therapeutics in 2023 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 20 increasing their positions, 6 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
more ownership
Funds ownership: →
233% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 6
113% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 8
25% more funds holding
Funds holding: 36 → 45 (+9)
Holders
45
Holding in Top 10
7
Calls
$8.21M
Puts
$5K
Top Buyers
| 1 | +$173M | |
| 2 | +$127M | |
| 3 | +$68.8M | |
| 4 |
VA
VR Adviser
New York
|
+$48.5M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$46M |
Top Sellers
| 1 | -$11.9M | |
| 2 | -$3.54M | |
| 3 | -$703K | |
| 4 |
MAM
Marquette Asset Management
Minneapolis,
Minnesota
|
-$154K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$153K |